A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy

Eph receptor A10 has a potential as a target for a prostate cancer therapy

(2014) Kazuya Nagano et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers

(2014) Kazuya Nagano et al.   JOURNAL OF CONTROLLED RELEASE

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells

(2014) Uwe Reusch et al.   mAbs

Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

(2014) Lindsey M. Hoffman et al.   Frontiers in Oncology

Emerging targeted therapies in triple-negative breast cancer

(2012) J. Crown et al.   ANNALS OF ONCOLOGY

The Eph/Ephrin family in cancer metastasis: communication at the service of invasion

(2012) Mustapha Kandouz   CANCER AND METASTASIS REVIEWS

Cancer Immunotherapy Using a Bispecific NK Receptor Fusion Protein that Engages both T Cells and Tumor Cells

(2011) T. Zhang et al.   CANCER RESEARCH

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer

(2011) J. Kondo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins

(2010) Sunao Imai et al.   BIOMATERIALS

Cytotoxic Enhancement of a Bispecific Diabody by Format Conversion to Tandem Single-chain Variable Fragment (taFv)

(2010) Ryutaro Asano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Understanding and circumventing resistance to anticancer monoclonal antibodies

(2010) Lina Reslan et al.   mAbs

Development trends for human monoclonal antibody therapeutics

(2010) Aaron L. Nelson et al.   NATURE REVIEWS DRUG DISCOVERY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2

(2009) M. Jager et al.   CANCER RESEARCH

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab

(2009) Dirk Nagorsen et al.   LEUKEMIA & LYMPHOMA

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY